T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly

in European Journal of Endocrinology
View More View Less
  • 1 Department of Medicine, Endocrinology Section, Pituitary Center Rotterdam, The Netherlands
  • 2 Department of Radiology, Erasmus University Medical Center, Rotterdam, The Netherlands
  • 3 Department of Biostatistics, Erasmus University Medical Center
  • 4 Department of Endocrinology, Centre Hospitalier Universitaire de Liège, Domaine Universitaire du Sart Tilman, Liège, Belgium

Correspondence should be addressed to E C Coopmans; Email: e.coopmans@erasmusmc.nl
Restricted access

Objective

T2-signal intensity and somatostatin (SST) receptor expression are recognized predictors of therapy response in acromegaly. We investigated the relationship between these predictors and the hormonal and tumoral responses to long-acting pasireotide (PAS-LAR) therapy, which were also compared with responsiveness to first-generation somatostatin receptor ligands (SRLs).

Design

The PAPE study is a cohort study.

Methods

We included 45 acromegaly patients initially receiving SRLs, followed by combination therapy with pegvisomant, and finally PAS-LAR. We assessed tumor volume reduction (≥25% from baseline), IGF-1 levels (expressed as the upper limit of normal), and T2-weighted MRI signal and SST receptor expression of the adenoma.

Results

Patients with significant tumor shrinkage during PAS-LAR showed higher IGF-1 levels during PAS-LAR (mean (S.D.): 1.36 (0.53) vs 0.93 (0.43), P = 0.020), less IGF-1 reduction after first-generation SRLs (mean (S.D.): 0.55 (0.71) vs 1.25 (1.07), P = 0.028), and lower SST2 receptor expression (median (IQR): 2.0 (1.0–6.0) vs 12.0 (7.5–12.0), P = 0.040). Overall, T2-signal intensity ratio was increased compared with baseline (mean (S.D.): 1.39 (0.56) vs 1.25 (0.52), P = 0.017) and a higher T2-signal was associated with lower IGF-1 levels during PAS-LAR (β: −0.29, 95% CI: −0.56 to −0.01, P = 0.045). A subset of PAS-LAR treated patients with increased T2-signal intensity achieved greater reduction of IGF-1 (mean (S.D.): 0.80 (0.60) vs 0.45 (0.39), P = 0.016).

Conclusions

Patients unresponsive to SRLs with a lower SST2 receptor expression are more prone to achieve tumor shrinkage during PAS-LAR. Surprisingly, tumor shrinkage is not accompanied by a biochemical response, which is accompanied with a higher T2-signal intensity.

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 1373 1373 52
Full Text Views 157 157 5
PDF Downloads 118 118 5
  • 1

    Melmed S. Acromegaly pathogenesis and treatment. Journal of Clinical Investigation 2009 119 31893202. (https://doi.org/10.1172/JCI39375)

    • Search Google Scholar
    • Export Citation
  • 2

    Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, Strasburger CJ, Luger A, Clemmons DR, Giustina A. A Consensus Statement on acromegaly therapeutic outcomes. Nature Reviews: Endocrinology 2018 14 552561. (https://doi.org/10.1038/s41574-018-0058-5)

    • Search Google Scholar
    • Export Citation
  • 3

    Signifor LAR (package insert). East Hanover: Novartis Pharmaceuticals Corporation, 2014.

  • 4

    Signifor LAR (summary of product characteristics). Basel: Novartis Pharma AG, 2014.

  • 5

    Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ & Hermosillo Resendiz K et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. Journal of Clinical Endocrinology and Metabolism 2014 99 791799. (https://doi.org/10.1210/jc.2013-2480)

    • Search Google Scholar
    • Export Citation
  • 6

    Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I & Lievre KK et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet: Diabetes and Endocrinology 2014 2 875884. (https://doi.org/10.1016/S2213-8587(14)70169-X)

    • Search Google Scholar
    • Export Citation
  • 7

    Muhammad A, van der Lely AJ, Delhanty PJD, Dallenga AHG, Haitsma IK, Janssen J, Neggers S. Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and first-generation somatostatin analogues (PAPE study). Journal of Clinical Endocrinology and Metabolism 2017 103 586595. (https://doi.org/10.1210/jc.2017-02017)

    • Search Google Scholar
    • Export Citation
  • 8

    Muhammad A, Coopmans EC, Delhanty PJD, Dallenga AHG, Haitsma IK, Janssen JAMJL, Van der Lely AJ, Neggers SJCMM. Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study. European Journal of Endocrinology 2018 179 269277. (https://doi.org/10.1530/EJE-18-0353)

    • Search Google Scholar
    • Export Citation
  • 9

    Potorac I, Petrossians P, Daly AF, Alexopoulou O, Borot S, Sahnoun-Fathallah M, Castinetti F, Devuyst F, Jaffrain-Rea ML & Briet C et al. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocrine-Related Cancer 2016 23 871881. (https://doi.org/10.1530/ERC-16-0356)

    • Search Google Scholar
    • Export Citation
  • 10

    Potorac I, Petrossians P, Daly AF, Schillo F, Ben Slama C, Nagi S, Sahnoun M, Brue T, Girard N & Chanson P et al. Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocrine-Related Cancer 2015 22 169177. (https://doi.org/10.1530/ERC-14-0305)

    • Search Google Scholar
    • Export Citation
  • 11

    Heck A, Ringstad G, Fougner SL, Casar-Borota O, Nome T, Ramm-Pettersen J, Bollerslev J. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clinical Endocrinology 2012 77 7278. (https://doi.org/10.1111/j.1365-2265.2011.04286.x)

    • Search Google Scholar
    • Export Citation
  • 12

    Hagiwara A, Inoue Y, Wakasa K, Haba T, Tashiro T, Miyamoto T. Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 2003 228 533538. (https://doi.org/10.1148/radiol.2282020695)

    • Search Google Scholar
    • Export Citation
  • 13

    Shen M, Zhang Q, Liu W, Wang M, Zhu J, Ma Z, He W, Li S, Shou X & Li Y et al. Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly. Neuroradiology 2016 58 10571065. (https://doi.org/10.1007/s00234-016-1728-4)

    • Search Google Scholar
    • Export Citation
  • 14

    Bonneville F, Riviere LD, Petersenn S, Bevan J, Houchard A, Sert C, Caron PJ & PRIMARYS Study group. MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post-hoc analysis. European Journal of Endocrinology 2019 180 155164. (https://doi.org/10.1530/EJE-18-0254)

    • Search Google Scholar
    • Export Citation
  • 15

    Gatto F, Feelders RA, van der Pas R, Kros JM, Waaijers M, Sprij-Mooij D, Neggers SJ, van der Lelij AJ, Minuto F & Lamberts SW et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism 2013 98 E66E71. (https://doi.org/10.1210/jc.2012-2609)

    • Search Google Scholar
    • Export Citation
  • 16

    Casar-Borota O, Heck A, Schulz S, Nesland JM, Ramm-Pettersen J, Lekva T, Alafuzoff I, Bollerslev J. Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. Journal of Clinical Endocrinology and Metabolism 2013 98 E1730E1739. (https://doi.org/10.1210/jc.2013-2145)

    • Search Google Scholar
    • Export Citation
  • 17

    Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Molecular and Cellular Endocrinology 2008 286 6974. (https://doi.org/10.1016/j.mce.2007.09.006)

    • Search Google Scholar
    • Export Citation
  • 18

    Ibanez-Costa A, Rivero-Cortes E, Vazquez-Borrego MC, Gahete MD, Jimenez-Reina L, Venegas-Moreno E, de la Riva A, Arraez , Gonzalez-Molero I & Schmid HA et al. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro. Journal of Endocrinology 2016 231 135145. (https://doi.org/10.1530/JOE-16-0332)

    • Search Google Scholar
    • Export Citation
  • 19

    Gatto F, Feelders RA, Franck SE, van Koetsveld PM, Dogan F, Kros JM, Neggers SJCMM, van der Lely AJ, Lamberts SWJ & Ferone D et al. In vitro head-to-head comparison Between octreotide and pasireotide in GH-secreting pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 2017 102 20092018. (https://doi.org/10.1210/jc.2017-00135)

    • Search Google Scholar
    • Export Citation
  • 20

    Manolopoulou J, Alami Y, Petersenn S, Schopohl J, Wu Z, Strasburger CJ, Bidlingmaier M. Automated 22-kD growth hormone–specific assay without interference from pegvisomant. Clinical Chemistry 2012 58 14461456. (https://doi.org/10.1373/clinchem.2012.188128)

    • Search Google Scholar
    • Export Citation
  • 21

    Bidlingmaier M, Friedrich N, Emeny RT, Spranger J, Wolthers OD, Roswall J, Korner A, Obermayer-Pietsch B, Hubener C & Dahlgren J et al. Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. Journal of Clinical Endocrinology and Metabolism 2014 99 17121721. (https://doi.org/10.1210/jc.2013-3059)

    • Search Google Scholar
    • Export Citation
  • 22

    Lundin P, Pedersen F. Volume of pituitary macroadenomas: assessment by MRI. Journal of Computer Assisted Tomography 1992 16 519528. (https://doi.org/10.1097/00004728-199207000-00004)

    • Search Google Scholar
    • Export Citation
  • 23

    Muhammad A, Coopmans EC, Gatto F, Franck SE, Janssen JAMJL, van der Lely AJ, Hofland LJ, Neggers SJCMM. Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression. Journal of Clinical Endocrinology and Metabolism 2019 104 915924. (https://doi.org/10.1210/jc.2018-01524)

    • Search Google Scholar
    • Export Citation
  • 24

    Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Der Pathologe 1987 8 138140.

    • Search Google Scholar
    • Export Citation
  • 25

    Neggers SJ, Franck SE, de Rooij FW, Dallenga AH, Poublon RM, Feelders RA, Janssen JA, Buchfelder M, Hofland LJ & Jorgensen JO et al. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism 2014 99 36443652. (https://doi.org/10.1210/jc.2014-2032)

    • Search Google Scholar
    • Export Citation
  • 26

    Coopmans EC, van der Lely AJ, Schneiders JJ, Neggers SJCMM. Potential antitumour activity of pasireotide on pituitary tumours in acromegaly. Lancet: Diabetes and Endocrinology 2019 7 425426. (https://doi.org/10.1016/S2213-8587(19)30113-5)

    • Search Google Scholar
    • Export Citation
  • 27

    Bronstein MD, Fleseriu M, Neggers S, Colao A, Sheppard M, Gu F, Shen CC, Gadelha M, Farrall AJ & Hermosillo Resendiz K et al. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, phase III study. BMC Endocrine Disorders 2016 16 16. (https://doi.org/10.1186/s12902-016-0096-8)

    • Search Google Scholar
    • Export Citation
  • 28

    Besser GM, Burman P, Daly AF. Predictors and rates of treatment-resistant tumor growth in acromegaly. European Journal of Endocrinology 2005 153 187193. (https://doi.org/10.1530/eje.1.01968)

    • Search Google Scholar
    • Export Citation
  • 29

    Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R & van der Lely AJ et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 2004 89 15771585. (https://doi.org/10.1210/jc.2003-031344)

    • Search Google Scholar
    • Export Citation
  • 30

    Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A, Ouafik LH. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. Journal of Clinical Endocrinology and Metabolism 2000 85 781792. (https://doi.org/10.1210/jcem.85.2.6338)

    • Search Google Scholar
    • Export Citation
  • 31

    Plockinger U, Albrecht S, Mawrin C, Saeger W, Buchfelder M, Petersenn S, Schulz S. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. Journal of Clinical Endocrinology and Metabolism 2008 93 12031210. (https://doi.org/10.1210/jc.2007-1986)

    • Search Google Scholar
    • Export Citation
  • 32

    Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. Journal of Clinical Endocrinology and Metabolism 1988 67 6973. (https://doi.org/10.1210/jcem-67-1-69)

    • Search Google Scholar
    • Export Citation
  • 33

    Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE & Vance ML et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 11711177. (https://doi.org/10.1056/NEJM200004203421604)

    • Search Google Scholar
    • Export Citation
  • 34

    Heck A, Emblem KE, Casar-Borota O, Ringstad G, Bollerslev J. MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly. Endocrine 2016 53 327330. (https://doi.org/10.1007/s12020-015-0816-2)

    • Search Google Scholar
    • Export Citation